JP2016505003A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016505003A5 JP2016505003A5 JP2015549902A JP2015549902A JP2016505003A5 JP 2016505003 A5 JP2016505003 A5 JP 2016505003A5 JP 2015549902 A JP2015549902 A JP 2015549902A JP 2015549902 A JP2015549902 A JP 2015549902A JP 2016505003 A5 JP2016505003 A5 JP 2016505003A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- biological sample
- mammalian
- binding
- vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims 30
- 201000011510 cancer Diseases 0.000 claims 30
- 238000000034 method Methods 0.000 claims 30
- 239000012472 biological sample Substances 0.000 claims 21
- 229920001184 polypeptide Polymers 0.000 claims 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims 18
- 108090000623 proteins and genes Proteins 0.000 claims 13
- 102000004169 proteins and genes Human genes 0.000 claims 13
- 229960005486 vaccine Drugs 0.000 claims 13
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 12
- 229960002685 biotin Drugs 0.000 claims 6
- 235000020958 biotin Nutrition 0.000 claims 6
- 239000011616 biotin Substances 0.000 claims 6
- 239000003638 chemical reducing agent Substances 0.000 claims 6
- 239000002563 ionic surfactant Substances 0.000 claims 6
- 230000002265 prevention Effects 0.000 claims 6
- 239000002904 solvent Substances 0.000 claims 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 5
- 239000007788 liquid Substances 0.000 claims 5
- 238000001556 precipitation Methods 0.000 claims 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 4
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 claims 4
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 claims 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000003495 polar organic solvent Substances 0.000 claims 3
- 239000002244 precipitate Substances 0.000 claims 3
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 claims 2
- 108090001008 Avidin Proteins 0.000 claims 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 2
- 108090001090 Lectins Proteins 0.000 claims 2
- 102000004856 Lectins Human genes 0.000 claims 2
- 108010090804 Streptavidin Proteins 0.000 claims 2
- 230000002152 alkylating effect Effects 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 claims 2
- 239000002198 insoluble material Substances 0.000 claims 2
- 239000002523 lectin Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000002195 soluble material Substances 0.000 claims 2
- 238000000638 solvent extraction Methods 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 claims 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims 2
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 1
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 claims 1
- 229960002433 cysteine Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 claims 1
- YFVGRULMIQXYNE-UHFFFAOYSA-M lithium;dodecyl sulfate Chemical compound [Li+].CCCCCCCCCCCCOS([O-])(=O)=O YFVGRULMIQXYNE-UHFFFAOYSA-M 0.000 claims 1
- 108010087904 neutravidin Proteins 0.000 claims 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 1
- 229940023143 protein vaccine Drugs 0.000 claims 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 claims 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2012905667 | 2012-12-24 | ||
| AU2012905669 | 2012-12-24 | ||
| AU2012905667A AU2012905667A0 (en) | 2012-12-24 | Vaccines for treatment of cancer | |
| AU2012905669A AU2012905669A0 (en) | 2012-12-24 | Vaccine booster | |
| AU2013203806 | 2013-04-11 | ||
| AU2013203806A AU2013203806B2 (en) | 2012-12-24 | 2013-04-11 | Vaccines for the treatment or prevention of cancer |
| AU2013903592 | 2013-09-18 | ||
| AU2013903592A AU2013903592A0 (en) | 2013-09-18 | Vaccines for the treatment or prevention of cancer | |
| PCT/AU2013/001523 WO2014100857A1 (en) | 2012-12-24 | 2013-12-24 | Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018017162A Division JP2018111695A (ja) | 2012-12-24 | 2018-02-02 | がんの治療のためのワクチン及びワクチン有効性を増強するための組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016505003A JP2016505003A (ja) | 2016-02-18 |
| JP2016505003A5 true JP2016505003A5 (cg-RX-API-DMAC7.html) | 2017-02-09 |
| JP6286445B2 JP6286445B2 (ja) | 2018-02-28 |
Family
ID=53547734
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015549902A Expired - Fee Related JP6286445B2 (ja) | 2012-12-24 | 2013-12-24 | がんの治療のためのワクチン及びワクチン有効性を増強するための組成物 |
| JP2018017162A Pending JP2018111695A (ja) | 2012-12-24 | 2018-02-02 | がんの治療のためのワクチン及びワクチン有効性を増強するための組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018017162A Pending JP2018111695A (ja) | 2012-12-24 | 2018-02-02 | がんの治療のためのワクチン及びワクチン有効性を増強するための組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10357538B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2934578B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6286445B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2013370932B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2934958A1 (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ629700A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014100857A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2934578B1 (en) * | 2012-12-24 | 2018-11-21 | Northern Sydney Local Health District | Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy |
| WO2017136539A1 (en) | 2016-02-04 | 2017-08-10 | Hare Joshua M | Mesenchymal stem cells as vaccine adjuvants and methods for using the same |
| KR20190003456A (ko) * | 2016-04-01 | 2019-01-09 | 아프세스 게엠베하 & 씨오. 카게 | 면역치료의 항-종양 활성을 높이기 위한 중간엽 줄기세포 |
| US12253490B2 (en) | 2018-03-19 | 2025-03-18 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| US12259355B2 (en) | 2018-03-19 | 2025-03-25 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| CN111868085B (zh) * | 2018-03-19 | 2024-11-05 | 瑞泽恩制药公司 | 微芯片毛细管电泳测定法及试剂 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62221636A (ja) * | 1986-03-20 | 1987-09-29 | Chemo Sero Therapeut Res Inst | Ｂ型肝炎ウイルス抗原蛋白の可溶化方法 |
| US5030621A (en) * | 1987-04-23 | 1991-07-09 | Bystryn Jean Claude | Shed melanoma antigen compositions |
| HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| US6379671B1 (en) * | 1996-08-19 | 2002-04-30 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the breast |
| EP1015024A1 (en) * | 1997-09-20 | 2000-07-05 | Osiris Therapeutics, Inc. | Antigen presenting mesenchymal stem cells |
| AT408615B (de) | 1998-09-15 | 2002-01-25 | Immuno Ag | Neue influenzavirus-impfstoffzusammensetzung |
| GB9923176D0 (en) | 1999-09-30 | 1999-12-01 | Smithkline Beecham Biolog | Novel composition |
| AU2002220265A1 (en) * | 2000-11-03 | 2002-05-15 | University Of Vermont And State Agricultural College | Compositions for inhibiting grb7 |
| CA2477411A1 (en) * | 2002-03-02 | 2003-09-12 | Board Of Regents, The University Of Texas | Local production and/or delivery of anti-cancer agents by stromal cell precursors |
| ES2395126T3 (es) | 2003-02-28 | 2013-02-08 | Agenus Inc. | Uso de lectinas para promover la oligomerización de glicoproteínas y de moléculas antigénicas |
| AU2003903317A0 (en) | 2003-06-27 | 2003-07-10 | Proteome Systems Intellectual Property Pty Ltd | Method of isolating a protein |
| US20050239897A1 (en) | 2004-03-22 | 2005-10-27 | Pittenger Mark F | Mesenchymal stem cells and uses therefor |
| US20080095749A1 (en) * | 2004-03-22 | 2008-04-24 | Sudeepta Aggarwal | Mesenchymal stem cells and uses therefor |
| AR054822A1 (es) | 2005-07-07 | 2007-07-18 | Sanofi Pasteur | Emulsion inmuno adyuvante |
| KR101022401B1 (ko) * | 2005-09-29 | 2011-03-15 | 아주대학교산학협력단 | 자살유전자를 발현하는 중간엽 줄기세포를 포함하는 암치료용 조성물 |
| CN1887296B (zh) * | 2006-07-31 | 2011-05-25 | 南京大学生物制药工程研究中心 | 一种诱导抗肿瘤免疫的方法及其在制药中的应用 |
| US8685728B2 (en) * | 2008-01-31 | 2014-04-01 | Rutgers The State University Of New Jersey | Kit containing stem cells and cytokines for use in attenuating immune responses |
| US8771705B2 (en) * | 2009-07-30 | 2014-07-08 | Healthbanks Biotech Co., Ltd. | Combination of protein vaccine and mesenchymal stem cells for treating cancer |
| US20120263685A1 (en) * | 2009-10-08 | 2012-10-18 | Rnl Bio Co., Ltd | Anti-tumor composition comprising human-derived adult stem cells |
| WO2011060244A1 (en) * | 2009-11-12 | 2011-05-19 | The Texas A & M University System | Spheroidal aggregates of mesenchymal stem cells |
| KR20120132183A (ko) * | 2011-05-27 | 2012-12-05 | 포항공과대학교 산학협력단 | 종양 조직에서 유래한 나노소포체 및 이를 이용한 암 백신 |
| WO2013040649A1 (en) | 2011-09-23 | 2013-03-28 | Cell Ideas Pty Ltd | Therapeutics using adipose cells and cell secretions |
| EP2934578B1 (en) * | 2012-12-24 | 2018-11-21 | Northern Sydney Local Health District | Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy |
-
2013
- 2013-12-24 EP EP13867300.9A patent/EP2934578B1/en not_active Not-in-force
- 2013-12-24 EP EP18182531.6A patent/EP3446708A1/en not_active Withdrawn
- 2013-12-24 CA CA2934958A patent/CA2934958A1/en not_active Abandoned
- 2013-12-24 WO PCT/AU2013/001523 patent/WO2014100857A1/en not_active Ceased
- 2013-12-24 JP JP2015549902A patent/JP6286445B2/ja not_active Expired - Fee Related
- 2013-12-24 NZ NZ629700A patent/NZ629700A/en not_active IP Right Cessation
- 2013-12-24 AU AU2013370932A patent/AU2013370932B2/en not_active Ceased
- 2013-12-24 US US14/655,088 patent/US10357538B2/en not_active Expired - Fee Related
-
2018
- 2018-02-02 JP JP2018017162A patent/JP2018111695A/ja active Pending
-
2019
- 2019-06-12 US US16/438,703 patent/US20190358291A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016505003A5 (cg-RX-API-DMAC7.html) | ||
| Darbre | Aluminium and the human breast | |
| Das et al. | The induction of angiogenesis by cerium oxide nanoparticles through the modulation of oxygen in intracellular environments | |
| Acunzo et al. | TCTP as therapeutic target in cancers | |
| Jeon et al. | Side-effect test of sorafenib using 3-D skin equivalent based on microfluidic skin-on-a-chip | |
| Ito et al. | Contrasting intra-and extracellular distribution of catalytic ferrous iron in ovalbumin-induced peritonitis | |
| Olsen et al. | Manipulation of cellular spheroid composition and the effects on vascular tissue fusion | |
| Herrera-Rincon et al. | Brief local application of progesterone via a wearable bioreactor induces long-term regenerative response in adult Xenopus hindlimb | |
| Xu et al. | Glycogen synthase kinase 3β dictates podocyte motility and focal adhesion turnover by modulating paxillin activity: implications for the protective effect of low-dose lithium in podocytopathy | |
| Del Turco et al. | Cytocompatibility evaluation of glycol-chitosan coated boron nitride nanotubes in human endothelial cells | |
| Xiao et al. | Anti-inflammatory treatment with β-asarone improves impairments in social interaction and cognition in MK-801 treated mice | |
| Pinto et al. | Cytotoxicity, genotoxicity, transplacental transfer and tissue disposition in pregnant rats mediated by nanoparticles: the case of magnetic core mesoporous silica nanoparticles | |
| JP2017527260A5 (cg-RX-API-DMAC7.html) | ||
| Zheng et al. | In vivo bioengineered ovarian tumors based on collagen, matrigel, alginate and agarose hydrogels: a comparative study | |
| Minullina et al. | Interfacing multicellular organisms with polyelectrolyte shells and nanoparticles: a Caenorhabtidis elegans study | |
| Roy et al. | Attenuation of cadmium-induced vascular toxicity by pro-angiogenic nanorods | |
| Samyesudhas et al. | Differential expression of ARID3B in normal adult tissue and carcinomas | |
| Nightingale et al. | The migrating gubernaculum grows like a “limb bud” | |
| Chen et al. | Redox disruption using electroactive liposome coated gold nanoparticles for cancer therapy | |
| Trac et al. | CD70-targeted micelles enhance HIF2α siRNA delivery and inhibit oncogenic functions in patient-derived clear cell renal carcinoma cells | |
| Tao et al. | Layered Double Hydroxide LDH-Loaded miR-141–3p Targets RAB10 Suppressing Cellular Autophagy to Reverse Paclitaxel Resistance in Breast Cancer | |
| Zhu et al. | Comparison study of bone defect healing effect of raw and processed pyritum in rats | |
| Su et al. | Novel in situ biosynthesized fluorescent zinc nanoclusters for specific cellular bio-imaging | |
| Čunderlíková | Clinical significance of immunohistochemically detected extracellular matrix proteins and their spatial distribution in primary cancer | |
| Altundag et al. | The role of HSP90 in Quercetin-induced apoptosis in human papillary thyroid (B-CPAP) cancer cells |